Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant conditions [1] and it is caused by loss of function mutations in the tumor suppressor gene NF1 [2] .
Abstract Neurofibromatosis type I is a genetic condition with an autosomal dominant transmission characterized by neurocutaneous involvement and a predisposition to tumor development. Central nervous system manifestations include benign areas of dysmyelination and possibly hazardous glial tumors whose clinical management may result challenging. Here, we report on three patients diagnosed with Neurofibromatosis type I whose brain MRI follow-up showed the presence of gadolinium-enhancing lesions which spontaneously regressed. In none of the three cases, the lesions showed any clinical correlate and eventually presented a striking reduction in size while gadolinium enhancement disappeared despite no specific therapy administration during the follow-up. Although their nature remains undetermined, these lesions presented a benign evolution. However, they might be misdiagnosed as potentially life-threatening tumors. Hitherto, a similar behavior has been described only in scattered cases and we believe these findings may be of particular interest for the clinical management of patients affected by neurofibromatosis type I. Size reduction and disappearance of gadolinium enhancement after 3 years a small gadolinium-enhancing lesion in the left cerebellar peduncle (patient #1), in the left cerebral peduncle (patient #2) and in the inferior portion of the right parietal lobe (patient #3). The lesions were relatively small (size range 3-14 mm), faintly T1 hypointense and moderately T2 hyperintense with mild focal swelling; contrast enhancement was marked. All the lesions did not show any clinical correlate and gadolinium enhancement eventually disappeared while the lesions showed striking reduction in size with residual faint T2 hyperintensity. In the first case, lesion regression developed after an initial enlargement (from 3 to 7 mm), followed by a 10-year period without changes; in the other two cases, the lesions regressed after a shorter period (one and 3 years, respectively). In patient #2, a new gadolinium-enhancing area was found in the left temporal lobe just after the disappearance of the peduncular lesion; at one-year follow-up MRI, this second lesion was also regressed (Fig. 1) .
Keywords
No clinical changes were detected during the follow-up of the lesions nor was any specific therapy administered.
OPG regression has been reported in patients affected by NF1. Less frequently, this evolution has been observed in extra-optic pathway tumors [7, 8] . A benign evolution of gadolinium-enhancing lesions has been reported only in few cases so far [10] [11] [12] [13] . In these rare cases, the lesions, which involved the brainstem [11] or the forebrain [10, 12, 13] showed a spontaneous regression during the follow-up without therapy administration or clinical changes.
In our cases, the disappearance of the gadoliniumenhanced lesion occurred in a short period of time in 2 out of the 3 NF1 patients, as in previously reported cases [10] , but unlike the patients with spontaneous involution of nonoptic gliomas [7, 8] .
Gadolinium enhancement represents a marker of bloodbrain barrier breakdown, but it does not always demonstrate the presence of tumor activity [15] . Our cases and the few already reported [10] [11] [12] [13] illustrate how also malignantlooking lesions may have unexpected positive evolution.
In patients affected with NF1, who can manifest both benign lesions as UBOs and proliferative glial tumors, clinical management may be challenging and the appearance of gadolinium-enhancing lesions may lead to an aggressive therapeutic approach.
Hence, in our opinion, these findings may play a role in the clinical management of patients affected by NF1 and suggest that the "wait and see" approach might be applied also in cases of enhancing lesions outside the optic pathway and the brainstem.
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The manuscript does not contain clinical studies, no Ethics Committee approval was necessary. Fig. 1 Patient #2 brain MRI follow-up, contrast-enhanced T1-weighted images (a-f). Upper row at the age of 12, axial (a) and coronal (b) images show an enhancing lesion involving the left cerebral peduncle; middle row at the age of 13, the midbrain lesion has disappeared (c) while a new enhancing lesion is evident in the white matter of the left temporal lobe (d). Note the mild atrophy of the left midbrain; lower row at the age of 15, the temporal lesion has disappeared (f)
